知名制药企业诺和诺德今日盘中股价大跌5.01%,引发外界高度关注。此前,美国政府公布了2027年医疗保险价格谈判的目标药品名单,其中包括诺和诺德公司的Wegovy减肥药和Ozempic糖尿病药物。
美国政府已选择15款针对疾病包括糖尿病、抑郁症在内的药物列入谈判范围。作为该地区开支最大的药物之一,诺和诺德的Wegovy和Ozempic预计售价将在明年遭大幅下调,削减幅度可能达38%至79%。
为了实现削减成本的目标,美国政府决定根据2022年签署的《通胀削减法案》,采取价格谈判的方式。如果药企拒绝参与谈判,将被罚款高达95%的药品销售额,或必须从医疗保险和医疗补助计划中撤出该产品。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.